The fittest founder in the room got cancer. Here’s how he used AI to fight back.

Conno Christou doesn’t leave things to chance. He tracks his sleep with a Whoop band, cross-references it with an Oura ring, and gets nearly 100 biomarkers checked every year. He had been doing the annual bloodwork for four consecutive years, following the protocols of longevity researchers like Peter Attia and Rhonda Patrick. He was optimizing his supplements, his circadian rhythm, his protein intake.

At 35, building his second company, he was as dialed-in on the latest in health research as anyone he knew. His last checkup, in 2025, was green across the board. “It was the best I’d had in years,” he says.

He didn’t think much of it at first. A week passed before he saw a doctor, who found two blood clots in his veins and scheduled surgery. But the pre-op exams changed everything. A doctor walked back into the room and told him the procedure wasn’t happening.

“We see an 11-by-11-by-8 centimeter mass behind your sternum,” the doctor said.

A biopsy confirmed what Christou had never before even contemplated. He had an aggressive, fast-growing form of non-Hodgkin’s lymphoma — a rare diagnosis affecting roughly one in 420,000 people, caused by a random genetic mutation with no connection to lifestyle, diet, or stress.

The tumor had only existed for about three months. In three more weeks, it would have reached stage four.

“Lucky in my unluckiness,” Christou told this editor this week from his home in Athens, where he lives part time. “It was only found because I went in for something else entirely.”

What followed was an education in the limits of the medical system, and in what a determined patient can do about that with tools now available.

His first oncologist, a renowned specialist, recommended the lighter of two available chemotherapy regimens. Christou booked his first infusion three days out. Then, the night before, he sought a second opinion.

That second doctor didn’t hesitate. He recommended the harder regimen — continuous in-hospital infusion, cycling every three weeks across six months — citing Christou’s specific pathology. The lighter treatment carried roughly a 60% success rate for his presentation. The aggressive one brought that number to around 85%. Two world-class doctors. Diametrically opposite recommendations.

“As founders, we hold the wheel,” Christou says of the propensity of many people to accept what they are told — and why more should not. “You hear many things. You don’t have to follow the first advice.”